Home › Trials › NCT06646471

Evaluating treatments for elderly patients with lung cancer

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly

Phase 4 Interventional Groupe Francais De Pneumo-Cancerologie · NCT06646471

This study is trying to see how well different treatments work for older adults with lung cancer and how these treatments affect their quality of life.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment500 (estimated)
Ages70 Years and up
SexAll
SponsorGroupe Francais De Pneumo-Cancerologie Academic / other
Locations41 sites (Aix-en-Provence and 40 other locations)
Trial IDNCT06646471 on ClinicalTrials.gov

What this trial studies

This study aims to collect real-life data on patients aged 70 and older who are receiving first-line treatment for non-small-cell lung cancer. It will characterize participants based on geriatric, biological, and cancer-related factors, while also documenting treatment modalities and their efficacy, safety, and impact on quality of life. Participants will be monitored according to standard clinical practices, with regular check-ups and assessments to evaluate their treatment outcomes. Additionally, specific sub-cohorts will be formed to explore uniform treatment strategies.

Who should consider this trial

Good fit: Ideal candidates are patients aged 70 and older with non-small-cell lung cancer who have not previously received systemic treatment.

Not a fit: Patients who have already been treated with systemic therapy for lung cancer or those under guardianship will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve treatment strategies and outcomes for elderly patients with lung cancer.

How similar studies have performed: Other studies focusing on elderly cancer patients have shown promising results, indicating that this approach is both relevant and potentially beneficial.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient ≥70 years
* Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
* Patient naïve to systemic anticancer treatment for bronchial neoplasia
* Patient covered by social security
* Patient eligible for systemic treatment
* Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.
* Patient able to understand the protocol
* Patient not opposed to the collection of data concerning him/her
* Signature of study consent form.

Exclusion Criteria:

* Patients under guardians or curators
* Patient not under the care of the investigating center and not monitored by the investigating center
* Patient already treated with systemic therapy for NSCLC

Where this trial is running

Aix-en-Provence and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non Small Cell Lung CancerLung Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.